Comparing available criteria for measuring brain metastasis response to immunotherapy.
Journal of neuro-oncology.
Times cited: 0
Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial.
The Lancet. Oncology.
Times cited: 30